TICKERNOMICS Sign up
Last Update: 2024-03-28 02:15:09
PIERIS PHARMACEUTICALS INC. ( PIRS ) https://www.pieris.com
0.19USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-87.30%
PIRS
SPY
32.74%
-92.77%
PIRS
SPY
92.93%
-94.39%
PIRS
SPY
224.41%
PIRS
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
17.96
6.05
0.34
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.66
0.38
0.59
-237.44
0.00
-0.18
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-60.49
100.00
-56.23
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.627
-257.52
-105.64
0.90
Other Earnings and Cash Flow Stats:
PIERIS PHARMACEUTICALS INC. ( PIRS ) Net Income TTM ($MM) is -39.67
PIERIS PHARMACEUTICALS INC. ( PIRS ) Operating Income TTM ($MM) is -51.00
PIERIS PHARMACEUTICALS INC. ( PIRS ) Owners' Earnings Annual ($MM) is -48.15
PIERIS PHARMACEUTICALS INC. ( PIRS ) Current Price to Owners' Earnings ratio is -0.39
PIERIS PHARMACEUTICALS INC. ( PIRS ) EBITDA TTM ($MM) is -47.62
PIERIS PHARMACEUTICALS INC. ( PIRS ) EBITDA Margin is -56.23%
Capital Allocation:
PIERIS PHARMACEUTICALS INC. ( PIRS ) has paid 0.00 dividends per share and bought back -24.68 million shares in the past 12 months
PIERIS PHARMACEUTICALS INC. ( PIRS ) has reduced its debt by 13.103 million USD in the last 12 months
Capital Structure:
PIERIS PHARMACEUTICALS INC. ( PIRS ) Interest-bearing Debt ($MM) as of last quarter is 0
PIERIS PHARMACEUTICALS INC. ( PIRS ) Annual Working Capital Investments ($MM) are 16
PIERIS PHARMACEUTICALS INC. ( PIRS ) Book Value ($MM) as of last quarter is 30
PIERIS PHARMACEUTICALS INC. ( PIRS ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
PIERIS PHARMACEUTICALS INC. ( PIRS ) has 32 million in cash on hand as of last quarter
PIERIS PHARMACEUTICALS INC. ( PIRS ) has 28 million of liabilities due within 12 months, and long term debt 0 as of last quarter
PIERIS PHARMACEUTICALS INC. ( PIRS ) has 98 common shares outstanding as of last quarter
PIERIS PHARMACEUTICALS INC. ( PIRS ) has 0 million USD of preferred stock value
Academic Scores:
PIERIS PHARMACEUTICALS INC. ( PIRS ) Altman Z-Score is -7.37 as of last quarter
PIERIS PHARMACEUTICALS INC. ( PIRS ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
PIERIS PHARMACEUTICALS INC. ( PIRS ) largest shareholder is owning shares at 0.00 ($MM) value
Christopher P Kiritsy(an insider) Bought 10000 shares of PIERIS PHARMACEUTICALS INC. ( PIRS ) for the amount of $8500.00 on 2023-05-25
14.99% of PIERIS PHARMACEUTICALS INC. ( PIRS ) is held by insiders, and 67.92% is held by institutions
PIERIS PHARMACEUTICALS INC. ( PIRS ) went public on 2015-04-13
Other PIERIS PHARMACEUTICALS INC. ( PIRS ) financial metrics:
FCF:-43.59
Unlevered Free Cash Flow:-76.79
EPS:-0.44
Operating Margin:-60.49
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-140.96
Beta:0.90
Buffet's Owners Earnings:-48.15
Price to Owner's Earnings:-0.39
About PIERIS PHARMACEUTICALS INC. ( PIRS ) :
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.